Previous close | 3.7600 |
Open | 3.6500 |
Bid | 3.5500 |
Ask | 5.1500 |
Strike | 50.00 |
Expiry date | 2025-03-21 |
Day's range | 3.6500 - 3.6500 |
Contract range | N/A |
Volume | |
Open interest | 264 |
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Despite becoming one a household name during the pandemic, Moderna stock has mostly fallen over the past three years amid slow sales.
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.